October round-up of pharma/biotech M&A activity

4 November 2016

With the US elections looming, October was a quiet month for mergers and acquisitions in pharma and biotech.

The biggest buys included ICU Medical's $1 billion purchase of Hospira Infusion Systems from US pharma giant Pfizer (NYSE: PFE), aimed at creating a pure-play infusion therapy company with estimated pro forma combined revenues of around $1.45 billion.

There was also Japan’s Astellas Pharma (TYO: 4503) buying of German biopharma company Ganymed Pharmaceuticals in a deal that could be worth up to 1.28 billion euros ($1.4 billion). The Tokyo-based company acquires the oncology treatment IMAB362, which it sees as a potential complementary product to its blockbuster prostate cancer drug Xtandi (enzalutamide).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK